An anti-Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at ...
ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, ...
Researchers have developed a promising nasal spray therapy targeting neuroinflammation in Alzheimer’s disease, potentially ...
A new therapy may delay Alzheimer's disease progression by years, according to a study by researchers at Texas A&M University ...
Once the nasal spray is absorbed through the membranes in the nose, it enters the bloodstream and works to stimulate melanin ...
Commercial launch of neffy®(epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by ...
The agreement grants ALK exclusive global rights to the neffy adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key ...
1d
Common decongestants may soon be pulled from shelves. The Food and Drug Administration (FDA) announced Wednesday its proposal ...
ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak ...
Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand ...
The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term cognitive and memory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback